Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis-Reference-Cited by-同舟云学术

Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis

Published:2020-03-31 Issue:7 Volume:43 Page:1015-1024
ISSN:0174-1551
Container-title:CardioVascular and Interventional Radiology
language:en
Short-container-title:Cardiovasc Intervent Radiol

Author:

Mosconi Cristina,Gramenzi Annagiulia,Biselli Maurizio,Cappelli Alberta,Bruno Antonio,De Benedittis Caterina,Cucchetti Alessandro,Modestino Francesco,Peta Giuliano,Bianchi Giampaolo,Trevisani Franco,Golfieri Rita

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging

Link

http://link.springer.com/content/pdf/10.1007/s00270-020-02451-3.pdf

Reference27 articles.

1. Liu Z, Jiang Y, Yuan H, Fang Q, Cai N, Suo C, Jin L, Zhang T, Chen X. The trends in incidence of primary liver cancer caused by specific etiologies: results from the global burden of disease study 2016 and implications for liver cancer prevention. J Hepatol. 2019;70:674–83.

2. Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156:477–91.

3. White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology. 2017;152:812–20.

4. Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, Yasui Y, Hosokawa T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010;52:518–27.

5. Cho SJ, Yoon JH, Hwang SS, Lee HS. Do young hepatocellular carcinoma patients with relatively good liver function have poorer outcomes than elderly patients? J Gastroenterol Hepatol. 2007;22:1226–311.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated;Hepatology International;2023-11-09

2. Safety and Effectiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Aged Greater versus Less Than 80 Years;Clinical Interventions in Aging;2023-11

3. A retrospective study of transarterial chemoembolization (TACE) combined with lenvatinib compared with TACE monotherapy for BCLC B2 stage hepatocellular carcinoma;Oncology Letters;2023-10-10

4. Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment;Cancers;2022-02-01

5. The duration of the conventional chemoembolization for hepatocellular carcinoma: factors affecting the procedural time;Hepatoma Research;2022